New York State Common Retirement Fund Grows Stock Position in CG Oncology, Inc. (NASDAQ:CGON)

New York State Common Retirement Fund boosted its stake in CG Oncology, Inc. (NASDAQ:CGON) by 16.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,996 shares of the company’s stock after acquiring an additional 2,000 shares during the quarter. New York State Common Retirement Fund’s holdings in CG Oncology were worth $401,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CGON. Amalgamated Bank raised its position in shares of CG Oncology by 107.6% during the 3rd quarter. Amalgamated Bank now owns 1,621 shares of the company’s stock valued at $61,000 after acquiring an additional 840 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of CG Oncology during the 4th quarter valued at approximately $68,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in CG Oncology in the third quarter worth $241,000. China Universal Asset Management Co. Ltd. acquired a new stake in CG Oncology in the fourth quarter worth $411,000. Finally, HighVista Strategies LLC acquired a new stake in CG Oncology in the third quarter worth $594,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

Wall Street Analysts Forecast Growth

CGON has been the topic of several analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $66.00 target price on shares of CG Oncology in a research report on Friday, December 6th. TD Cowen began coverage on CG Oncology in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of CG Oncology in a research note on Friday, January 10th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $65.14.

CG Oncology Trading Down 1.2 %

Shares of CG Oncology stock opened at $24.80 on Wednesday. The stock has a 50-day simple moving average of $28.82 and a 200-day simple moving average of $33.08. CG Oncology, Inc. has a 52-week low of $23.91 and a 52-week high of $46.99.

Insider Activity at CG Oncology

In other CG Oncology news, Director Hong Fang Song sold 700,000 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $28.00, for a total value of $19,600,000.00. Following the transaction, the director now owns 3,003,931 shares of the company’s stock, valued at approximately $84,110,068. The trade was a 18.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The disclosure for this sale can be found here. Insiders have sold a total of 702,000 shares of company stock valued at $19,664,200 in the last 90 days.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.